NVO Stock Price Today (October 2026) — Novo Nordisk A/S Analysis & Key Metrics 2026-10-08
Novo Nordisk A/S (NVO) is trading at $38.18, down 0.21% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $47.17 (23.5% upside).
- Volatility is moderate (32.95% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: steady revenue (2.10% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
NVO Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Novo Nordisk A/S - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $263.73B
P/E Ratio
Forward P/E: 13.29
Revenue Growth
Year over Year
Analyst Target
+23.5% upside potential
Key Investor Questions About NVO
What investors need to know before buying
Based on current market data, NVO presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 34.27)
- Fundamentals say: Mixed signals (nuanced financial profile)
NVO's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NVO investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $140.13B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, NVO stock traded between $35.12 and $64.16 and currently trades near the low end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 32.95% annualized volatility and β=1.07, the stock exhibits moderate correlation to market moves—making NVO suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Moderate ownership metrics suggest a balanced supply-demand dynamic.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Eli Lilly (LLY) vs. Novo Nordisk (NVO): Has the GLP-1 Race Changed the Moat?
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market’s view of the two companies has changed sharply. Since mid-2024, Novo’s stock has fallen roughly 74%, while Lilly’s has gained about 35%. That difference is also reflected in their valuations, […]
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.
Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product?
The drugmaker badly needs more clinical wins.
Viatris sues Novo Nordisk over generic Wegovy patent dispute
Investing.com -- Viatris filed a lawsuit against Novo Nordisk in Delaware federal court, requesting a determination that its planned generic version of Wegovy would not violate the Danish company's patent rights.
Novo Nordisk Changed the World With Its GLP-1 Weight-Loss Drugs. Now It Wants to Help Cure Baldness.
The Danish pharmaceutical giant that brought the world Ozempic may be ready to start researching a cure for hair loss. From a business perspective, it's a smart move.
Novo Nordisk's $1.3 Billion Deal Targets a Big Obesity-Drug Problem
The collaboration covers up to five programs in obesity, diabetes and other cardiometabolic diseases.
Novo Pays Up to $1.3 Billion for Nanexa's Drug Delivery Tech
Nanexa's shares more than doubled
Novo Nordisk Gets Regulatory Nod in Singapore for Wegovy Treatment of Certain Liver Ailments
Novo Nordisk (NVO) has won approval from Singapore authorities for the use of its weight-loss drug,
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?
Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.
Novo Nordisk Just Made a Surprising Move Beyond Weight Loss
The company aims to launch more than five potential blockbuster drugs by 2030.
Explore More Analysis for NVO
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 4, 2026
Frequently Asked Questions
Common investor questions about Novo Nordisk A/S
Novo Nordisk A/S (NVO) is currently trading at $38.18. The RSI (14-day) is at 34.3, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $47.17 implies 23.5% upside from current levels. Volatility is moderate at 33.0% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Novo Nordisk A/S (NVO): The trailing P/E ratio is 10.62, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 13.29. The PEG ratio is 3.14, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 5.58. Price-to-Sales is 0.44. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering NVO, the consensus price target is $47.17. This represents a 23.5% upside from the current price of $38.18. The range spans from a low target of $40.21 to a high target of $64.07, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Novo Nordisk A/S (NVO) pays a dividend with a current yield of approximately 4.71%. The annualized dividend rate is $11.70 per share. The payout ratio is 44.5%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Aug 17, 2026.
Key risks for Novo Nordisk A/S (NVO) investors include: 1. Moderate volatility (33.0% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Novo Nordisk A/S's (NVO) current debt and financial health profile: Total debt stands at $140.13B. The debt-to-equity ratio is 0.63x, which is moderate and generally manageable for most companies. The current ratio is 0.87, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.64. The company holds $44.98B in cash and equivalents. Free cash flow is positive at $37.67B, providing a cushion for debt servicing and shareholder returns.